Despite a few bright spots, the fundraising environment remains difficult for many venture investors. Biotechs that went public during the 2005-2007 window have largely underperformed, despite hitting the stock exchanges with what plenty of CEOs and VCs felt were artificially low prices negotiated by an oligarchy of biotech IPO buyers. Moreover, pharmaceutical companies have been buying fewer, not more, biotechs - even as more companies are seemingly created with acquisition, not IPO, in mind. Meanwhile, the M&A deals that do occur are increasingly risk-sharing affairs that resemble alliances, replete with earn-out payments triggered by development, regulatory, or commercial milestones. In short: good venture exits have been extremely hard to come by. And data from Elsevier's Strategic Transactions analyzed by START-UP suggest that although these risk-sharing deal structures may be a by-product of a miserable economy, they are likely to stick around regardless of any economic turnaround.
Ellen Foster Licking and Christopher Morrison
The public market debut of Anthera Pharmaceuticals Inc. was a closely watched affair.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
US green light will further expand sales of the prostate cancer blockbuster.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
